Skip to content
Medical Health Aged Care, National News Current Affairs

NEW GUIDELINES FOR PATIENTS & DENTISTS ON EARLY RELEASE OF SUPERANNUATION FOR DENTAL CARE

The Australian Dental Association 3 mins read

16.10.25

NEW GUIDELINES FOR DENTISTS & PATIENTS ON EARLY RELEASE OF 

SUPERANNUATION FOR DENTAL CARE

RADIO GRABS ATTACHED TO RELEASE

 CASE STUDY AVAILABLE FOR INTERVIEW

 

NEW GUIDELINES ON THE EARLY RELEASE OF SUPERANNUATION to fund dental treatment have today been released by the dental profession’s peak body, providing more clarity for both patient and dentist.

The guidelines come as the Australian Tax Office (ATO) was due to release its annual review of data today on the early release of superannuation, in which dental care rates as the second highest (1) reason for using the Compassionate Release of Super scheme (CRS).

"The ability to access superannuation early to pay for critical dental treatment is an important part of our health safety net,” said Australian Dental Association (ADA) President Dr Chris Sanzaro. “The scheme has provided welcome financial relief for tens of thousands of people needing urgent dental treatment.”

The new CRS guidelines produced by the ADA are designed to provide clarity for the applicant patient as well as remind dentists of their obligations. They also aim to clear up some of the misinformation surrounding the scheme, such as:

*Dentists can’t provide financial guidance to patients on the implications of withdrawing super to fund treatment - this can only be provided by a holder of an Australian Financial Services License;

*The clinician who wrote the patient’s report for the ATO doesn’t have to be the one doing the treatment;

*A dentist’s report must only recommend treatment for the life-threatening illness or injury, acute or chronic pain. No other work can be funded this way; 

*Dentists may ask for a deposit to cover clinic time, lab fees and associated expenses, but it’s not usual that all treatment is paid for upfront, and

*It’s recommended that dentists don’t advertise the CRS on their practice website, though its existence as a payment form can be mentioned to the patient.

The guidelines also seek to reiterate that CRS can only occur when there’s a life-threatening injury or illness, acute or chronic pain, or where dental treatment will help with a mental illness and there’s no other way to afford it. To fulfill these criteria there must be two reports from medical practitioners, one who must be a specialist or dentist. For an application to treat mental illness, a report from a specialist psychiatrist is required.

Dr Sanzaro said: “We’re also stressing that as well as reports, patients need a quote from the practitioner about the cost of treatment necessary to treat the acute condition, as well as an indication of future treatment and maintenance costs. That way there’s complete transparency for both sides.”

The CRS guidelines for dentists were developed out of a need to provide clarity around the system which has seen some cases of system abuse. The guidelines include information on advertising restrictions, presenting patients with all treatment options and costs, and rules around contributing to the medical reports which accompany the application.

The CRS guidelines for patients include how the money must be used, a reminder to patients their dentist cannot give financial advice and what some of the eligibility criteria are. They can be found on the ADA’s consumer website teeth.org.au and also here: https://teeth.org.au/compassionate-release-of-super-for-dental-treatment

Ends.

Background for News Editors:

The new rules have come out as the Australian Tax Office releases (16 October) its annual findings of applications for early release of super across a range of areas including dental, medical, IVF and disability.

Dental applications have been the second most common application reason. In 2024 the ATO received 31,780 dental applications and it approved 22,530 (1). The amount approved was $526.4m. In 2023 there were 20,960 dental applications and 14,020 approvals, totalling $313.4m.

Sources:

1.2024 data: https://www.ato.gov.au/about-ato/research-and-statistics/in-detail/super-statistics/early-release/compassionate-release-of-super/applications-received-and-approved

 RADIO GRABS ATTACHED TO RELEASE

To interview ADA President Dr Chris Sanzaro contact Media Advisor

Jenny Barlass 0497 748 331.

 

 


Contact details:

ADA Media Advisor Jenny Barlass

0497 748 331

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.